CLLS Investors Have Opportunity to Join Cellectis S.A. Fraud Investigation with SBS Law
For best results when printing this announcement, please click on link below: CLLS Investors Have Opportunity to Join Cellectis S.A. Fraud Investigation with SBS Law Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cellectis S.A. (“Cellectis” or “the Company”) (NASDAQ: CLLS ) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Cellectis announced on September 14, 2026, that it would prioritize in vivo gene editing therapies over CAR-T cell therapies. The Company also announced the discontinuation of development of certain CAR-T cell therapies. The Company’s Chief Medical Officer stated, "Cellectis is not able finance [Eti-cel and Lasme-cel] given the time lines that we have and the limited cash resources that we have." Based on this news, shares of Cellectis fell by almost 41% on the same day. If you are a shareholder who suffered a loss, click here to participate We also encourage you to contact Brian Schal
A. A. (“Cellectis” or “the Company”) (NASDAQ: CLLS ) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Cellectis announced on September 14, 2026, that it would prioritize in vivo gene editing therapies over CAR-T cell therapies. The Company also announced the discontinuation of development of certain CAR-T cell therapies. " Based on this news, shares of Cellectis fell by almost 41% on the same day. If you are a shareholder who suffered a loss, click here to participate We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge.
com). WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. com)